Previous 10 | Next 10 |
Shares of Citius Pharmaceuticals Inc. (NASDAQ:CTXR) traded at a new 52-week high today of $3.86. Approximately 2.8 million shares have changed hands today, as compared to an average 30-day volume of 6.3 million shares. Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is currently priced 17.5% a...
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) traded at a new 52-week high today of $3.79. Approximately 2.8 million shares have changed hands today, as compared to an average 30-day volume of 6.3 million shares. In the past 52 weeks, shares of Citius Pharmaceuticals Inc. have traded between...
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) finds itself up over 15% going into Tuesday’s market close after the Company announced that Dr. John Laffey, a leading scholar in Acute Respiratory Distress Syndrome (ARDS) and the use of cutting-edge therapies to treat acute lung...
Are These Biotech Penny Stocks Worth It? Finding the best biotech penny stocks to buy can be a challenge. As with any investment, there is quite a lot of work that should go into it. While biotech stocks do trade similarly to others, there are a few nuances that investors should conside...
IDMC meets on June 29 for Superiority review. Mino-Lok has no competition. Price target increased to $10. Mino-Lok has Fast Track designation. Enough cash through commercialization. For further details see: Citius: Halt For Superiority On The Horizon
Citius Pharmaceuticals Expands Scientific Advisory Board with Addition of Dr. John Laffey, Expert in Stem Cell and Gene Therapies for ARDS - Addition of leading scholar and KOL in acute respiratory distress syndrome (ARDS) to ARDS Scientific Advisory Board supports continued pro...
4 Biotech Penny Stocks For Your June Watchlist Are you considering buying penny stocks this June? Trading penny stocks has been extremely popular this year. With low prices and high volatility, the potential for rapid portfolio growth is an exciting prospect for investors to conside...
Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial - Independent Data Monitoring Committee (DMC) to review Mino-Lok® safety, superiority, and futility data at upcoming meeting scheduled for June 29, 2021- PR Newswire ...
Citius Pharmaceuticals to be Added to Russell 2000® Index PR Newswire CRANFORD, N.J. , June 7, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and comm...
Citius Pharmaceuticals Selected to Receive Best Poster Award at the International Society for Cell and Gene Therapy 2021 Annual Meeting Poster highlighting proof-of-concept study of Citius' iPSC-derived stem cell therapy in acute lung injury chosen for Best Poster Award at ISCT ...
News, Short Squeeze, Breakout and More Instantly...
Citius Pharmaceuticals Inc. Company Name:
CTXR Stock Symbol:
NASDAQ Market:
Citius Pharmaceuticals Inc. Website:
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical c...
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...